Interactions between apolipoprotein E and apolipoprotein(a) in patients with late-onset Alzheimer disease

Annals of Internal Medicine

Volumn 132, Issue 7, 2000, Pages 533-537

  Mooser, Vincent ^a   Helbecque, Nicole ^b   Miklossy, Judit ^c   Marcovina, Santica M ^d   Nicod, Pascal ^a   Amouyel, Philippe ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b INSTITUT PASTEUR DE LILLE   (France)

^c UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN E;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENOTYPE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; UNIVERSITY HOSPITAL;

EID: 0034603850     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-7-200004040-00004     Document Type: Article

References (24)

1. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease A meta-analysis APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349-56.
2. Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA, Steffens DC, Wyse BW, et al. ApoE genotype predicts when - not whether - one is predisposed to develop Alzheimer disease. Nat Genet. 1998;19:321-2.
3. Helbecque N, Richard F, Cottel D, Neuman E, Guez D, Amouyel P. The very low density lipoprotein (VLDL) receptor is a genetic susceptibility factor for Alzheimer disease in a European Caucasian population. Alzheimer Dis Assoc Disord. 1998;12:368-71.
4. Wavrant-DeVrièze F, Pérez-Tur J, Lambert JC, Frigard B, Pasquier F, Delacourte A, et al. Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimer's disease. Neurosci Lett 1997;227:68-70.
5. Williams KR, Saunders AM, Roses AD, Armati PJ. Uptake and internalization of exogenous apolipoprotein E3 by cultured human central nervous system neurons. Neurobiol Dis. 1998;5:271-9.
6. Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, et al. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell. 1999; 97:689-701.
7. Utermann G. The mysteries of lipoprotein(a). Science. 1989;246:904-10.
8. Hobbs HH, White AL. Lipoprotein(a): intrigues and insights. Curr Opin Lipidol. 1999;10:225-36.
9. Ramharack R, Spahr MA, Kreick JS, Sekerke CS. Expression of apolipoprctein[a] and plasminogen mRNAs in cynomolgus monkey liver and extrahepatic tissues. J Lipid Res. 1996;37:2029-40.
10. März W, Beckmann A, Scharnagl H, Siekmeier R, Mondorf U, Held I, et al. Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor. FEBS Lett. 1993;325: 271-5.
11. Argraves KM, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest. 1997;100:2170-81.
12. Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA. 1994;271:1004-10.
13. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41:246-55.
14. Fontana P, Mooser V, Bovet P, Shamlaye C, Burnand B, Lenain V, et al. Dose-dependent inverse relationship between alcohol consumption and serum Lp(a) levels in black African males. Arterioscler Thromb Vasc Biol. 1999; 19:1075-82.
15. Mooser V, Mancini FP, Bopp S, Pethö-Schramm A, Guerra R, Boerwinkle E, et al. Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma. Hum Mol Genet. 1995;4:173-81.
16. Hixson JE, Vernier DT. Restrict on isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res. 1990;31:545-8.
17. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, et al. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb. 1992;12:1214-26.
18. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90:52-60.
19. Mooser V, Scheer D, Marcovina SM, Wang J, Guerra R, Cohen J, et al. The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans. Am J Hum Genet. 1997;61:402-17.
20. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 1994;264:850-2.
21. Bard JM, Delattre-Lestavel S, Clavey V, Pont P, Derudas B, Parra HJ, et al. Isolation and characterization of two sub-species of Lp(a), one containing apo E and one free of apo E. Biochim Biophys Acta. 1992;1127:124-30.
22. van Barlingen HH, Kleinveld HA, Erkelens DW, de Bruin TW. Lipoprotem lipase-enhanced binding of lipoprotein(a) [Lp(a)] to heparan sulfate is improved by apolipoprotein E (apoE) saturation. secretion-capture process of apoE is a possible route for the catabolism of Lp(a). Metabolism. 1997;46: 650-5.
23. Lin H, Ignatescu M, Wilson JE, Roberts CR, Horley KJ, Winters GL, et al. Prominence of apolipoproteins B, (a), and E in the intimae of coronary arteries in transplanted human hearts: geographic relationship to vessel wall proteoglycans. J Heart Lung Transplant. 1996;15:1223-32.
24. Thillet J, Doucet C, Chapman J, Herbeth B, Cohen D, Faure-Delanef L. Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity: evidence from a large population of French centenarians. Atherosclerosis. 1998;136:389-94.